Midazolam
Epilepsy
Floatz Rating
BBB72/100
Confidence
Indicative
Sponsor
Haseki Training and Research Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06741930CT.gov Pro-Epileptic Effects of IV Ketamine | — | Completed | — | — | — |
NCT06056349CT.gov Benzodiazepine Study for the Treatment of Seizure Clusters in a Third Level Mexican Neurological Center | — | Unknown | — | — | — |
NCT05346666CT.gov Possible Immuno-Modulatory Effect of Tocilizumab in Patients With Refractory Status Epilepticus. | — | Unknown | — | — | — |
NCT02645279CT.gov Comparison of Oral 30 % Dextrose and iv Midazolam Sedation During MRI in Neonates | — | Unknown | — | — | — |
NCT02161185CT.gov A Long-term Safety and Tolerability Study of USL261 in Patients With Seizure Clusters | — | Terminated | — | — | — |
NCT02325583CT.gov Intraoral 30% Glucose Effect In Newborns | — | Completed | — | — | — |
NCT01999777CT.gov Study to Evaluate the Safety and Efficacy of USL261 in Patients With Increased Bouts of Seizure Activity in the EMU | — | Completed | — | — | — |
NCT01529034CT.gov Study to Evaluate the Long-term Safety and Tolerability of USL261 in Patients With Seizure Clusters | — | Terminated | — | — | — |
NCT01316445CT.gov Pharmacodynamics of Nasal and Buccal Midazolam Using EEG | — | Terminated | — | — | — |
NCT01390220CT.gov Study to Evaluate the Safety and Efficacy of USL261 (Intranasal Midazolam) in Patients With Seizure Clusters | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Epilepsy
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midazolam (this asset) | Haseki Training and Research Hospital | Approved | BBB · 72 |
| Topiramate | Université de Sherbrooke | P4 | BBB |
| Eslicarbazepine Acetate | Bial - Portela C S.A. | P4 | BBB |
| Lamotrigine | Assiut University | P4 | BBB |
| Levetiracetam | Beijing Tiantan Hospital | P4 | BBB |
| Neurotop | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Lacosamide | Second Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Valproic Acid | Sanofi | P4 | BBB |
| Perampanel | Humanis Saglık Anonim Sirketi | P4 | BB |
+42 more in the Epilepsy cohort
Other indications for Midazolam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuralgia | — | P4 | BBB · 75 |
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 75 |
| Choledocholithiasis | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Midazolam in Epilepsy. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/midazolam-epilepsy-28378
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →